Rani Therapeutics Highlights Promising Preclinical Data

Rani Therapeutics Holdings, Inc. Class A ( (RANI) ) has released its Q1 earnings. Here is a breakdown of the information Rani Therapeutics Holdings, Inc. Class A presented to its investors.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company specializing in the development of oral biologics and drugs, utilizing its proprietary RaniPill® capsule technology to potentially replace traditional injection methods. In its first-quarter 2025 financial report, Rani Therapeutics highlighted promising preclinical data for its RT-114 and RT-116 treatments, showcasing the potential of its RaniPill® platform to deliver obesity treatments orally. Key financial metrics revealed a decrease in research and development expenses to $6.6 million and general and administrative expenses to $5.6 million, resulting in a net loss of $12.7 million for the quarter. The company also reported cash, cash equivalents, and marketable securities totaling $15.9 million as of March 31, 2025. Looking ahead, Rani Therapeutics anticipates the initiation of a Phase 1 clinical trial for RT-114 in mid-2025, aiming to further validate its innovative oral delivery platform and address gaps in the obesity treatment landscape.